HRA Pharma Rare Diseases funds online hub for Cushing’s Syndrome

HRA Pharma Rare Diseases, an affiliate of global consumer healthcare company HRA Pharma, has announced it is funding an online platform containing information and news on Cushing’s Syndrome.

The ‘Cushing’s Hub’, developed by Springer Healthcare Education, is set to make all information on the rare condition available in one place for medical professionals to access.

Cushing’s Syndrome affects less than one in 10,000 people in the EU, and is categorised as a rare and severe condition caused by prolonged high levels of cortisol in the blood.

The new hub is managed by an independent editorial board consisting of three international Cushing’s Syndrome experts - Professor Frédéric Castinetti from France, Dr Niki Karavitaki from the UK and Associate Professor Dr Greisa Vila from Austria.

According to HRA Pharma Rare Diseases, the ‘Cushing’s Hub’ is the first online platform dedicated to all aspects of the rare condition.

“As a company which is dedicated to improving the lives of those with rare diseases, we felt it was crucial to support the development of a platform that can help healthcare professionals in the diagnosis, management and follow up of Cushing’s Syndrome. We are confident the platform will help improve the lives of many,” said Evelina Paberžė, COO of HRA Pharma Rare Diseases.